380 related articles for article (PubMed ID: 27045023)
1. Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.
Newick K; O'Brien S; Sun J; Kapoor V; Maceyko S; Lo A; Puré E; Moon E; Albelda SM
Cancer Immunol Res; 2016 Jun; 4(6):541-51. PubMed ID: 27045023
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
3. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
4. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.
Wang E; Wang LC; Tsai CY; Bhoj V; Gershenson Z; Moon E; Newick K; Sun J; Lo A; Baradet T; Feldman MD; Barrett D; Puré E; Albelda S; Milone MC
Cancer Immunol Res; 2015 Jul; 3(7):815-26. PubMed ID: 25941351
[TBL] [Abstract][Full Text] [Related]
5. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.
Liu X; Ranganathan R; Jiang S; Fang C; Sun J; Kim S; Newick K; Lo A; June CH; Zhao Y; Moon EK
Cancer Res; 2016 Mar; 76(6):1578-90. PubMed ID: 26979791
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
7. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
8. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
[TBL] [Abstract][Full Text] [Related]
9. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
10. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
11. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
[TBL] [Abstract][Full Text] [Related]
12. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
13. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
Riese MJ; Wang LC; Moon EK; Joshi RP; Ranganathan A; June CH; Koretzky GA; Albelda SM
Cancer Res; 2013 Jun; 73(12):3566-77. PubMed ID: 23576561
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
Huang H; Xiang J
Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
[TBL] [Abstract][Full Text] [Related]
15. Driving an improved CAR for cancer immunotherapy.
Huang X; Yang Y
J Clin Invest; 2016 Aug; 126(8):2795-8. PubMed ID: 27454296
[TBL] [Abstract][Full Text] [Related]
16. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
17. Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency.
Mosenden R; Singh P; Cornez I; Heglind M; Ruppelt A; Moutschen M; Enerbäck S; Rahmouni S; Taskén K
J Immunol; 2011 May; 186(9):5119-30. PubMed ID: 21430226
[TBL] [Abstract][Full Text] [Related]
18. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
19. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
